Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August 
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip 
Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Nike China Strategy to Lift Margins Despite $1 Billion Sales Hit, Bernstein Says 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
BHP Port Hedland Strike Set to Proceed as Wage Talks Continue 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion 
BASKING RIDGE, N.J., April 03, 2018 -- Caladrius Biosciences, Inc. (Nasdaq:CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications, announces today that Joe Talamo, Senior Vice President and Chief Financial Officer, will present a corporate overview at The MicroCap Conference on Monday, April 9th at 1:30 p.m. Eastern time. The conference will be held April 9-10, 2018 at the Essex House in New York City.
Mr. Talamo’s presentation will not be webcast, but a copy of the corporate presentation is available in the Investor Relations section of the Company’s website at www.caladrius.com/investors.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications. The Company is investigating its lead product candidate, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes, in an ongoing Phase 2 trial. CLBS14, CD34 cell therapy intended as a treatment for coronary microvascular dysfunction and refractory angina, is Caladrius’ proprietary and patent protected formulation of CD34 cells designed specifically to enhance the potency of the CD34 cells for repair and regeneration of cardiovascular tissue. Its companion product, CLBS12, is formulated specifically for intramuscular administration for the treatment of lower extremity ischemia. A phase 2 study of CLBS12 as a treatment for critical limb ischemia is enrolling in Japan, a successful outcome of which will qualify the program for consideration of early conditional approval based on discussions with the Japanese regulatory authorities as provided for under Japan’s progressive regenerative medicine regulations. For more information about Caladrius, please visit www.caladrius.com.
Contacts:
Caladrius Biosciences, Inc.
John Menditto
Executive Director, Investor Relations and Corporate Communications Phone: +1-908-842-0084
Email: [email protected]
LHA Investor Relations
Miriam Weber Miller
Senior Vice President
Phone: +1-212-838-3777
Email: [email protected]
